Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers

Bancroft, Elizabeth K. ; Page, Elizabeth C. ; Brook, Mark N. ; Pope, Jennifer ; Thomas, Sarah ; Myhill, Kathryn ; Helfand, Brian T. ; Talaty, Pooja ; Ong, Kai Ren and Douglas, Emma , et al. (2024) In BJU International 134(3). p.484-500
Abstract

Objectives: To report the long-term outcomes from a longitudinal psychosocial study that forms part of the ‘Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls’ (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2). Subjects and Methods: Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following... (More)

Objectives: To report the long-term outcomes from a longitudinal psychosocial study that forms part of the ‘Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls’ (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2). Subjects and Methods: Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge. Results: A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P < 0.001). Cancer risk perceptions reflected information provided during genetic counselling and participants had good levels of knowledge, although this declined over time. Conclusion: This is the first study to report the longitudinal psychosocial impact of a targeted PrCa screening programme for BRCA1 and BRCA2 carriers. The results reassure that an annual PSA-based screening programme does not have an adverse impact on psychosocial health or health-related quality of life in these higher-risk individuals. These results are important as more PrCa screening is targeted to higher-risk groups.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
contributor
LU orcid
author collaboration
publishing date
type
Contribution to journal
publication status
published
subject
keywords
BRCA1, BRCA2, genetic screening, prostate cancer, psychosocial, quality of life
in
BJU International
volume
134
issue
3
pages
484 - 500
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:85199880453
  • pmid:38839570
ISSN
1464-4096
DOI
10.1111/bju.16432
language
English
LU publication?
no
additional info
Publisher Copyright: © 2024 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International.
id
ad9d8fde-af75-4c8d-b07f-ad3801cf6939
date added to LUP
2024-09-08 13:37:17
date last changed
2025-07-14 17:35:00
@article{ad9d8fde-af75-4c8d-b07f-ad3801cf6939,
  abstract     = {{<p>Objectives: To report the long-term outcomes from a longitudinal psychosocial study that forms part of the ‘Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls’ (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2). Subjects and Methods: Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge. Results: A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P &lt; 0.001). Cancer risk perceptions reflected information provided during genetic counselling and participants had good levels of knowledge, although this declined over time. Conclusion: This is the first study to report the longitudinal psychosocial impact of a targeted PrCa screening programme for BRCA1 and BRCA2 carriers. The results reassure that an annual PSA-based screening programme does not have an adverse impact on psychosocial health or health-related quality of life in these higher-risk individuals. These results are important as more PrCa screening is targeted to higher-risk groups.</p>}},
  author       = {{Bancroft, Elizabeth K. and Page, Elizabeth C. and Brook, Mark N. and Pope, Jennifer and Thomas, Sarah and Myhill, Kathryn and Helfand, Brian T. and Talaty, Pooja and Ong, Kai Ren and Douglas, Emma and Cook, Jackie and Rosario, Derek J. and Salinas, Monica and Buys, Saundra S. and Anson, Jo and Davidson, Rosemarie and Longmuir, Mark and Side, Lucy and Eccles, Diana M. and Tischkowitz, Marc and Taylor, Amy and Cruellas, Mara and Ballestero, Eduard Perez and Cleaver, Ruth and Varughese, Mohini and Barwell, Julian and LeButt, Mandy and Greenhalgh, Lynn and Hart, Rachel and Azzabi, Ashraf and Jobson, Irene and Cogley, Lynn and Evans, D. Gareth and Rothwell, Jeanette and Taylor, Natalie and Hogben, Matthew and Saya, Sibel}},
  issn         = {{1464-4096}},
  keywords     = {{BRCA1; BRCA2; genetic screening; prostate cancer; psychosocial; quality of life}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{484--500}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{BJU International}},
  title        = {{The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers}},
  url          = {{http://dx.doi.org/10.1111/bju.16432}},
  doi          = {{10.1111/bju.16432}},
  volume       = {{134}},
  year         = {{2024}},
}